A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469

Pharmacogenetics and Genomics

Volumn 24, Issue 2, 2014, Pages 129-132

  Ramírez, Jacqueline ^a   Kim, Tae Won ^a   Liu, Wanqing ^a   Myers, Jamie L ^a   Mirkov, Snezana ^a   Owzar, Kouros ^b   Watson, Dorothy ^b   Mulkey, Flora ^b   Gamazon, Eric R ^a   Stock, Wendy ^a   Undevia, Samir ^a   Innocenti, Federico ^a   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

aldehyde oxidase I; clearance; phase I; XK469

Indexed keywords

ALDEHYDE OXIDASE; ALDEHYDE OXIDASE I; GYRASE INHIBITOR; MICRORNA; UNCLASSIFIED DRUG; XK 469;

ADVANCED CANCER; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; COHORT ANALYSIS; DNA FLANKING REGION; DNA METHYLATION; DRUG CLEARANCE; GENE EXPRESSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTRON; LEUKEMIA; PHARMACOGENETICS; PHENOTYPE; PLASMA CLEARANCE; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR;

ALDEHYDE OXIDASE; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; COHORT STUDIES; GENETIC VARIATION; GENOTYPE; HUMANS; LIVER; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT LOCI; QUINOXALINES;

EID: 84894908420     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000023     Document Type: Article

References (11)

1. Undevia SD, Innocenti F, Ramirez J, House L, Desai AA, Skoog LA, et al. A phase I and pharmacokinetic study of the quinoxaline antitumour agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer 2008; 44:1684-1692
2. Stock W, Undevia SD, Bivins C, Ravandi F, Odenike O, Faderl S, et al. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs 2008; 26:331-338
3. Hartmann T, Terao M, Garattini E, Teutloff C, Alfaro JF, Jones JP, et al. The impact of single nucleotide polymorphisms on human aldehyde oxidase. Drug Metab Dispos 2012; 40:856-864
4. Innocenti F, Cooper GM, Stanaway IB, Gamazon ER, Smith JD, Mirkov S, et al. Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet 2011; 7:e1002078
5. Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet 2007; 3:1724-1735
6. Smith MA, Marinaki AM, Arenas M, Shobowale-Bakre M, Lewis CM, Ansari A, et al. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Drug Metab Dispos 2012; 40:856-864
7. Kurzawski M, Dziewanowski K, Safranow K, Drozdzik M. Polymorphism of genes involved in purine metabolism (XDH, AOX1, MOCOS) in kidney transplant recipients receiving azathioprine. Ther Drug Monit 2012; 34: 266-274
8. Steinberg KK, Relling MV, Gallagher ML, Greene CN, Rubin CS, French D, et al. Genetic studies of a cluster of acute lymphoblastic leukemia cases in Churchill County, Nevada. Environ Health Perspect 2007; 115: 158-164
9. Neumeier M, Weigert J, Schä ffler A, Weiss TS, Schmidl C, Bü ttner R, et al. Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro. Biochem Biophys Res Commun 2006; 350:731-735
10. Kim JW, Kim ST, Turner AR, Young T, Smith S, Liu W, et al. Identification of new differentially methylated genes that have potential functional consequences in prostate cancer. PLoS One 2012; 7:e48455
11. Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, Tran TD. Aldehyde oxidase: An enzyme of emerging importance in drug discovery. J Med Chem 2010; 53:8441-8460